logo
The Baseline
14 Aug 2026
Five stocks to buy from analysts this week - August 14, 2026
By Abdullah Shah

1. ASK Automotive:

ICICI Securities maintains its ‘Buy’ call on this auto parts & equipment manufacturer, with a higher target price of Rs 750, an upside of 15.9%. ASK delivered a stellar Q1FY27 performance as revenue jumped 52.1% YoY and net profit climbed 28.8%. Analysts Ronak Mehta and Vivek Kumar attribute this surge to market share gains in the aluminium lightweighting precision segment, recovering exports, and pricing adjustments that passed on raw material costs.

The company continues to outperform the two-wheeler sector. It is capturing higher kit values as the industry shifts toward electric vehicles, expanding its passenger vehicle presence, and winning new client contracts. Thanks to strong export orders, management raised its FY27 revenue growth guidance from mid-teens to high-teens. Near-term industry tailwinds like GST rate cuts, favourable monsoon trends, and commission payouts should improve fuel demand.

Mehta and Kumar expect EBITDA margins to reach management's target of 13–14%. Key profit drivers include shutting down the low-margin wheel assembly business and boosting productivity at the Rajasthan plant. They project ASK to deliver revenue and net profit CAGRs of 17.4% and 21.4%, respectively, through FY29.

2. Aurobindo Pharma: 

Motilal Oswal retains its ‘Buy’ rating on this pharma major, with a higher target price of Rs 1,860, implying an upside of 14%. Aurobindo posted impressive Q1FY27 results. Revenue rose 18.1% YoY, led by robust sales in European, US, and anti-retroviral formulation markets. Net profit surged 25.2%, thanks to an improved product mix and wider margins in Europe and complex formulations.

Analysts Tushar Manudhane and Eshita Jain highlight the biosimilars & biologics segment as a powerful long-term growth driver. Commercial launches, expanding global partnerships, higher capacity, and entry into regulated markets should propel this division beyond traditional generics. Management is also raising capacity for contract manufacturing, expecting this business to scale rapidly by FY29.

Manudhane and Eshita point out that the acquisition of generics manufacturer Lannett gives Aurobindo a US manufacturing facility. This deal opens new avenues in controlled substances and government contracts while leveraging Lannett's existing industry partnerships. Management reaffirmed its FY27 guidance for double-digit revenue improvement and EBITDA margins above 21%. Consequently, analysts project revenue and net profit to grow at CAGRs of 15% and 21%, respectively, over FY27–28.

3. Rainbow Childrens Medicare: 

Anand Rathi maintains its ‘Buy’ rating on this hospital operator and raises its target price to Rs 1,750, implying an upside of around 23.5%. Rainbow posted good Q1FY27 results, with revenue up 33% YoY. Strong patient volumes from rising inpatient discharges, outpatient visits, and childbirths, alongside the rapid ramp-up of new hospitals, pushed performance higher.

Analysts Himanshu Binani and Anubhav Sangal emphasise that Rainbow is expanding into new regions while strengthening its footprint in core markets. The company plans to enter Mumbai with a 100-bed hospital in Malad, while adding capacity in Nellore and Guntur. It will open its Indore hospital in Q3, with four more facilities planned over the coming years. This expansion will boost total bed capacity from 2,565 to nearly 3,725.

Binani and Sangal believe Rainbow's focus on pediatric and maternity care grants it an edge in India’s underdeveloped healthcare market. Ramp-ups at newer hospitals, steady output at mature facilities, and planned capacity additions will drive near-term revenue growth. Analysts project revenue and EBITDA to expand at CAGRs of 19% and 21% between FY27-28.

4. Subros:

Khambatta Securities maintains its ‘Buy’ rating on this small-cap auto components manufacturer, with a target price of Rs 897, an upside of 17.8%. Subros’ revenue jumped 17.5% YoY in Q1FY27, driven by strong sales volumes and recent product launches. However, surging raw material, transport, and employee costs reduced EBITDA margins by 151 basis points.

Management anticipates that the rise in FY27 revenue will mirror the broader auto industry's single-digit pace. A margin rebound may take time, as the company negotiates price hikes with clients while cutting internal costs. Meanwhile, analysts note that mandatory AC rules for trucks should help Subros increase its truck air-conditioning revenue from Rs 260 crore in FY26 to Rs 300 crore in FY27.

Analysts expect new ventures and capacity expansion to drive long-term growth. The company plans to start production at the new Haryana plant in Q3 to support Maruti Suzuki's Sonipat expansion. Another facility in Gujarat will manufacture electric and conventional compressors. Subros is also partnering with DENSO and Toyota Industries to localise electric compressor production by FY28, aiming to cut imports and boost margins.

5. Sonata Software: 

Deven Choksey reiterates its ‘Buy’ rating on this IT services company, with a target price of Rs 372, an upside of 14.3%. Sonata is benefiting from rising demand as it shifts toward AI-driven technology services. Its AI order book grew 27% QoQ, while potential AI deal values rose 21%. The company also added seven new clients for the third consecutive quarter. However, heavy investments and lower billable employee utilisation squeezed Q1FY27 margins.

Management expects revenue and margins to rebound as recently won large contracts ramp up. Most of these projects will reach full scale during Q2, supporting stronger H2FY27 performance. Analyst Neel Mehta believes the continued expansion of Harmoni.AI, its proprietary platform that automates software development and business processes, should bring future growth. A recent partnership with Microsoft should also unlock new opportunities across AI, cloud, and data services.

Mehta anticipates domestic expansion to stem from Sonata's $340 million AI deal pipeline, expanding large contracts, and improved employee utilisation. He also notes that the domestic India business could drive growth through recurring cloud revenues and managed services.

 

Note: These recommendations are from various analysts and are not recommendations by Trendlyne.

(You can find all analyst picks here)

More from The Baseline
More from Satyam Kumar
Recommended